Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Reconsolidation Blockade with Propranolol as a Potential Novel Treatment for Tobacco Adddiction

EF 2015-16

Résumé
Tobacco use is the leading cause of preventable death in Canada. Only a small percentage of smokers who attempt to quit each year are successful in remaining abstinent, indicating that novel smoking cessation treatments are necessary to ensure cessation and relapse prevention. One such novel treatment targets the most probable mechanism that mediates craving and relapse in smokers: smoking cue exposures trigger smoking cravings and in turn lead to relapse. This project thus proposes to investigate a treatment to reduce the salience of smoking cues through the use of a memory reconsolidation blockade, which involves disrupting recalled memories prior to their restabilization, as they are labile and can be pharmacologically modified during this time.In this study, the β-adrenergic receptor antagonist propranolol will be used to block reconsolidation of smoking cues. My hypothesis is that post-reactivation administration of propranolol followed by exposure to smoking cues will reduce the salience of smoking memories and of cigarette cravings. This hypothesis will be tested using proximal smoking cues, such as a pack of cigarettes and a lighter, and videos depicting smokers in different contexts to reactivate smoking memory associations. Following reactivation, smokers will be randomized to two groups: one group will receive a placebo and the other will receive propranolol. Outcome measures will include self-rated craving states and physiological responses to smoking-related cues, immediately after reactivation and after a delay of one week. If the group differences between change scores are significant, reconsolidation blockade through use of propranolol may qualify as a potential tobacco dependence intervention treatment.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
350118
Name
Barnabe Alexandra
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Reconsolidation Blockade with Propranolol as a Potential Novel Treatment for Tobacco Adddiction
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Addiction Treatment; Cigarette; Cravings; Cue Reactivity; Memory; Nicotine; Propranolol; Reconsolidation; Reconsolidation Blockade; Smoking Cessation
Abstract
Tobacco use is the leading cause of preventable death in Canada. Only a small percentage of smokers who attempt to quit each year are successful in remaining abstinent, indicating that novel smoking cessation treatments are necessary to ensure cessation and relapse prevention. One such novel treatment targets the most probable mechanism that mediates craving and relapse in smokers: smoking cue exposures trigger smoking cravings and in turn lead to relapse. This project thus proposes to investigate a treatment to reduce the salience of smoking cues through the use of a memory reconsolidation blockade, which involves disrupting recalled memories prior to their restabilization, as they are labile and can be pharmacologically modified during this time.In this study, the β-adrenergic receptor antagonist propranolol will be used to block reconsolidation of smoking cues. My hypothesis is that post-reactivation administration of propranolol followed by exposure to smoking cues will reduce the salience of smoking memories and of cigarette cravings. This hypothesis will be tested using proximal smoking cues, such as a pack of cigarettes and a lighter, and videos depicting smokers in different contexts to reactivate smoking memory associations. Following reactivation, smokers will be randomized to two groups: one group will receive a placebo and the other will receive propranolol. Outcome measures will include self-rated craving states and physiological responses to smoking-related cues, immediately after reactivation and after a delay of one week. If the group differences between change scores are significant, reconsolidation blockade through use of propranolol may qualify as a potential tobacco dependence intervention treatment.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Barnabe, Alexandra
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~